MAIA Biotechnology Inc. Common Stock (MAIA)

FairStock Score: 14/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at MAIA and see a clinical-stage biotech with 13 employees, no reported revenue, and a lead product, Ateganosine, still in clinical development for non-small cell lung cancer. That is not a business in the Graham sense; it is a scientific option. The filings show net losses of $19.8M in fiscal 2023, the year ended 2023-12-31; $23.3M in fiscal 2024, the year ended 2024-12-31; and $22.4M in fiscal 2025, the year ended 2025-12-31. In fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was $7.9M, or $-0.13 per diluted share. Trailing free cash flow is negative $22.6M, and FairStock calculates an FCF yield of -32.0%. Financial health is poor: Piotroski F-Score 0/9, Altman Z-Score 0.39, and an overall FairStock Score of 14/100. The FairStock Lynch category is 'none' because losses occurred in each of the last four years. At $1.16 on 2026-10-13, market cap is $70.6M. The P/E is -1.87, P/B is 3.41, ROE is -218.68%, and ROCE is -92.10%, all FairStock calculations. I see no competitive moat: no approved product, no revenue, and no earnings to value. The stock has traded between $0.87 and $3.19 in the past year, beta 0.28, but low beta does not make a pre-revenue biotech safe. The only rational value here rests on future trial success, which is binary and outside my circle of competence. Without a margin of safety from assets or earnings, I would call it speculative, not a value investment.

In plain English: MAIA Biotechnology is a tiny clinical-stage biotech with 13 employees. It is testing a cancer treatment, mainly for non-small cell lung cancer, but it has no reported revenue and has lost money every year shown, including $22.4 million in fiscal 2025 (the year ended 2025-12-31). At $1.16 on 2026-10-13, the price looks speculative rather than cheap because there are no profits or meaningful sales to support it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer